Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: elab), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PMGC Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PMGC Holdings's regulatory disclosures and financial reporting.
PMGC Holdings Inc. is implementing a 1-for-6 reverse stock split of its common stock. Every six existing shares are being combined into one share, effective at 12:00 a.m. Eastern time on March 10, 2026. The company anticipates having approximately 3,248,764 shares of common stock outstanding immediately prior to the split and approximately 541,461 shares outstanding immediately after it.
After the amendment, authorized capital will consist of 83,333,334 shares of common stock and 500,000,000 shares of preferred stock, for a total of 583,333,334 authorized shares. The trading symbol remains “ELAB”, the par value is unchanged, and no fractional shares will be issued, with holders receiving one full share in lieu of any fractional position. Outstanding stock awards, options, warrants, and plan reserves are being adjusted proportionally, and the warrants’ exercise prices are being revised to reflect the new share count.
PMGC Holdings Inc. entered into a new secured prepaid equity financing with an investor, referred to as Secured Pre-Paid Purchase #4, on February 6, 2026. The Fourth Pre-Paid Purchase has an original principal amount of
Most of the purchase price,
After the effective date, the investor may require the company to issue and sell common shares at a price equal to
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Biosciences, announced the filing of ten new U.S. patent applications for its EL-22 and EL-32 technologies targeting animal health and agricultural markets.
The applications cover use of these candidates to encourage muscle growth and increase muscle yield in livestock, aquaculture species, and poultry, along with concepts for reducing gaseous emissions in livestock and mitigating eutrophic conditions in aquaculture. NorthStrive’s lead asset, EL-22, uses an engineered probiotic approach to help preserve muscle during weight loss treatments such as GLP-1 receptor agonists, and this portfolio aims to extend the platform beyond human aesthetics into farmed animal productivity and environmental impact.
PMGC Holdings Inc. is registering and offering up to $1,222,168 of its common stock under a shelf registration, selling shares directly to Streeterville Capital through an equity line of credit structure. Shares will be issued against pre-paid purchase balances at a discount to recent volume‑weighted average prices.
The company has used multiple pre-paid purchases to raise cash and faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $18,034,757 as of September 30, 2025 and recurring net losses. Management plans to use net proceeds for general corporate purposes and potential acquisitions, which are not yet identified, and warns that further issuances under the equity facility and other derivative securities could significantly dilute existing shareholders and pressure the Nasdaq‑listed stock price.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 11,828 securities of PMGC Holdings Inc., representing about 1.0% of the company’s common stock. These securities include 11,828 warrants to purchase shares of common stock.
L1 Capital reports sole voting and dispositive power over these 11,828 securities and no shared power. The ownership percentage is based on 1,185,795 shares of common stock outstanding as referenced in a recent prospectus supplement. The filer also certifies the position is not held to change or influence control of PMGC Holdings.
PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., has signed a definitive, exclusive license agreement with Modulant Biosciences LLC for its EL-22 and EL-32 programs in animal health. Modulant receives a worldwide (excluding Korea), royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from these myostatin- and activin-A–targeting probiotic technologies for non-human animal applications, including use as a feed additive. Modulant is responsible for all development, regulatory, manufacturing, and commercialization activities. The agreement converts a previously announced binding term sheet into a full contract, but PMGC cautions there is no assurance Modulant will successfully obtain approvals or commercialize products.
PMGC Holdings Inc. director Jeffrey Parry reports beneficial ownership of 3 shares of common stock of PMGC Holdings Inc. (ELAB) on a post-reverse-stock-split basis. He also holds options to purchase 1 share of common stock at an exercise price of $26,264 and options to purchase 4 shares at $98,000, both granted on September 30, 2022 under the company’s 2020 Equity Incentive Plan. The filing explains that all share and exercise price figures have been adjusted to reflect multiple reverse stock splits completed between 2024 and 2026.
PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, entered into a material license agreement with Modulant Biosciences for non‑human animal health products. Modulant receives an exclusive, royalty-bearing, worldwide license (excluding Korea) to develop and commercialize products using Northstrive’s myostatin and Activin‑A intellectual property.
Northstrive and Modulant will co-own any new intellectual property created under the relationship, each with a half interest. Modulant will share a percentage of commercialization revenue with Northstrive up to a defined threshold, then at a lower rate, and is bound by a broad non‑compete on competing myostatin or Activin‑A products. Human pharmaceutical uses are explicitly excluded, and the agreement includes detailed sublicensing, indemnification, confidentiality, and termination provisions.
PMGC Holdings Inc. (ELAB) director Juliana Daley filed an amended initial ownership report updating her equity holdings on a post-reverse-split basis. She reports beneficial ownership of 1 share of common stock and options to purchase 4 shares of common stock.
The options, granted on June 1, 2023 as partial compensation for her independent director services, have an exercise price of $98,000 per share, vest 25% on April 1, 2024 and the remainder over 36 months, and reflect multiple reverse stock splits completed between November 2024 and January 2026.
PMGC Holdings Inc. completed the acquisition of Machining, Inc., a California precision CNC machining company, on February 2, 2026. PMGC acquired 100% of the shares for a total purchase price of $2,449,148.08, including $2,250,000 in cash, a $130,000 fixed cash balance and a $69,148 net working capital adjustment subject to post-closing true-up.
The seller may earn up to an additional $1,250,000 through two revenue-based earnouts tied to performance in the 12‑month periods ending December 31, 2026 and December 31, 2027. Machining, Inc. generated revenue of $3,042,701 for the year ended December 31, 2024, serving medical, aerospace, semiconductor, biotech, pharmaceutical and transportation markets.
PMGC entered into a short transition services agreement and a lease for the facility, and obtained three‑year non‑compete and non‑solicitation commitments from the seller. The filing also includes audited and unaudited financial statements of Machining, Inc. and pro forma combined financial information.